YumanityLogo.jpg
Yumanity Therapeutics Announces Definitive Agreements for Two Strategic Transactions
June 06, 2022 06:30 ET | Yumanity Therapeutics Inc
Yumanity Therapeutics, Inc. to sell its clinical-stage product candidate YTX-7739 as well as its unpartnered discovery-stage neuroscience product candidates and targets to Janssen Pharmaceutica NV in...
YumanityLogo.jpg
Yumanity Therapeutics Reports First Quarter 2022 Financial Results and Recent Corporate Developments
May 12, 2022 16:45 ET | Yumanity Therapeutics Inc
BOSTON, May 12, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (Nasdaq: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying...
YumanityLogo.jpg
Yumanity Therapeutics Reports Full-Year 2021 Financial Results and Recent Corporate Developments
March 24, 2022 16:15 ET | Yumanity Therapeutics Inc
BOSTON, March 24, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (Nasdaq: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying...
YumanityLogo.jpg
Yumanity Therapeutics Exploring Strategic Alternatives to Enhance Shareholder Value and Announces Restructuring
February 17, 2022 08:30 ET | Yumanity Therapeutics Inc
BOSTON, Feb. 17, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (Nasdaq: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying...
YumanityLogo.jpg
Yumanity Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
February 04, 2022 18:48 ET | Yumanity Therapeutics Inc
BOSTON, Feb. 04, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying...
YumanityLogo.jpg
Yumanity Reports Partial Clinical Hold by U.S. FDA on Multidose Clinical Trials for YTX-7739  
January 19, 2022 07:30 ET | Yumanity Therapeutics Inc
BOSTON, Jan. 19, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (Nasdaq: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying...
YumanityLogo.jpg
Yumanity’s Approach to Neurodegenerative Diseases Validated by Two External Collaborations
January 11, 2022 08:00 ET | Yumanity Therapeutics Inc
Yumanity achieves research milestone in its collaboration with Merck; Yumanity to receive $5 million milestone payment Michael J. Fox Foundation awards grant to accelerate early proof-of-concept...
YumanityLogo.jpg
Yumanity Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 05, 2022 16:05 ET | Yumanity Therapeutics Inc
BOSTON, Jan. 05, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying...
YumanityLogo.jpg
Yumanity Therapeutics to Present at the H.C. Wainwright BioConnect Conference
January 04, 2022 08:00 ET | Yumanity Therapeutics Inc
BOSTON, Jan. 04, 2022 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying...
YumanityLogo.jpg
Yumanity Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
December 03, 2021 18:00 ET | Yumanity Therapeutics Inc
BOSTON, Dec. 03, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying...